CA3044364A1 - 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease - Google Patents
5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease Download PDFInfo
- Publication number
- CA3044364A1 CA3044364A1 CA3044364A CA3044364A CA3044364A1 CA 3044364 A1 CA3044364 A1 CA 3044364A1 CA 3044364 A CA3044364 A CA 3044364A CA 3044364 A CA3044364 A CA 3044364A CA 3044364 A1 CA3044364 A1 CA 3044364A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- disease
- pharmaceutically acceptable
- acceptable salt
- ethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382584.7 | 2016-12-01 | ||
| EP16382584 | 2016-12-01 | ||
| PCT/IB2017/057587 WO2018100557A1 (en) | 2016-12-01 | 2017-12-01 | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3044364A1 true CA3044364A1 (en) | 2018-06-07 |
Family
ID=57517838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3044364A Pending CA3044364A1 (en) | 2016-12-01 | 2017-12-01 | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11938122B2 (https=) |
| EP (1) | EP3548026B1 (https=) |
| JP (1) | JP7040798B2 (https=) |
| KR (1) | KR102595034B1 (https=) |
| CN (1) | CN110022877B (https=) |
| AU (1) | AU2017370003B2 (https=) |
| BR (1) | BR112019011334A2 (https=) |
| CA (1) | CA3044364A1 (https=) |
| CY (1) | CY1124116T1 (https=) |
| DK (1) | DK3548026T3 (https=) |
| EA (1) | EA201991304A1 (https=) |
| ES (1) | ES2867300T3 (https=) |
| HR (1) | HRP20210576T1 (https=) |
| HU (1) | HUE054346T2 (https=) |
| LT (1) | LT3548026T (https=) |
| MX (1) | MX379710B (https=) |
| PL (1) | PL3548026T3 (https=) |
| PT (1) | PT3548026T (https=) |
| SI (1) | SI3548026T1 (https=) |
| WO (1) | WO2018100557A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7040798B2 (ja) | 2016-12-01 | 2022-03-23 | ミノリックス セラピューティクス エセ．エレ． | 非アルコール性脂肪性肝疾患を処置するための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオン |
| EP3801515B1 (en) | 2018-06-06 | 2025-04-09 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases |
| US20230172921A1 (en) * | 2020-04-30 | 2023-06-08 | Minoryx Therapeutics S.L. | Leriglitazone for treating lung inflammation and interstitial lung disease |
| EP4642456A1 (en) | 2022-12-28 | 2025-11-05 | Minoryx Therapeutics S.L. | Optimized dosing of leriglitazone |
| WO2024231881A2 (en) | 2023-05-09 | 2024-11-14 | Minoryx Therapeutics S.L. | Polymorphic forms and formulations of leriglitazone |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5441971A (en) | 1991-04-11 | 1995-08-15 | The Upjohn Company | Thiazolidinedione derivatives, production and use thereof |
| DE69231886T2 (de) | 1991-04-11 | 2002-03-28 | Pharmacia & Upjohn Co., Kalamazoo | Thiazolidindionderivate, herstellung und anwendung |
| WO1993022445A1 (en) | 1992-05-05 | 1993-11-11 | The Upjohn Company | A process for producing pioglitazone metabolite |
| US5952509A (en) | 1996-06-27 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Production of benzaldehyde compounds |
| US6191154B1 (en) | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| AU2002367154A1 (en) | 2001-12-21 | 2003-07-15 | Smithkline Beecham Corporation | Dosing regimen for ppar-gamma activators |
| US8993773B2 (en) | 2002-07-16 | 2015-03-31 | Cadila Healthcare Limited | Process to prepare pioglitazone via several novel intermediates |
| GB0510469D0 (en) | 2005-05-23 | 2005-06-29 | Leuven K U Res & Dev | Insulin sensitization to slow down pubertal tempo and to augment pubertal growth |
| PL2001468T3 (pl) | 2006-03-16 | 2013-03-29 | Metabolic Solutions Dev Co Llc | Analogi tiazolidynodionu |
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
| WO2013040419A1 (en) | 2011-09-14 | 2013-03-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating hyperprolinemia-associated mental disorders |
| US8865747B2 (en) | 2012-03-23 | 2014-10-21 | Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) | Pioglitazone for use in the treatment of adrenoleukodystrophy |
| US20140178456A1 (en) | 2012-08-30 | 2014-06-26 | Udaya Sankar Devanaboyina | Methods and compositions for treating type 2 diabetes and related conditions |
| WO2014152843A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
| EP3094328B1 (en) | 2014-01-15 | 2020-08-19 | Poxel SA | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
| EA202091120A3 (ru) * | 2014-04-02 | 2020-12-30 | Минорикс Терапьютикс С.Л. | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы |
| JP7040798B2 (ja) | 2016-12-01 | 2022-03-23 | ミノリックス セラピューティクス エセ．エレ． | 非アルコール性脂肪性肝疾患を処置するための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオン |
-
2017
- 2017-12-01 JP JP2019529165A patent/JP7040798B2/ja not_active Expired - Fee Related
- 2017-12-01 EP EP17817175.7A patent/EP3548026B1/en active Active
- 2017-12-01 DK DK17817175.7T patent/DK3548026T3/da active
- 2017-12-01 LT LTEP17817175.7T patent/LT3548026T/lt unknown
- 2017-12-01 ES ES17817175T patent/ES2867300T3/es active Active
- 2017-12-01 KR KR1020197019093A patent/KR102595034B1/ko active Active
- 2017-12-01 CN CN201780074388.1A patent/CN110022877B/zh active Active
- 2017-12-01 AU AU2017370003A patent/AU2017370003B2/en not_active Ceased
- 2017-12-01 HU HUE17817175A patent/HUE054346T2/hu unknown
- 2017-12-01 US US16/465,043 patent/US11938122B2/en active Active
- 2017-12-01 HR HRP20210576TT patent/HRP20210576T1/hr unknown
- 2017-12-01 WO PCT/IB2017/057587 patent/WO2018100557A1/en not_active Ceased
- 2017-12-01 EA EA201991304A patent/EA201991304A1/ru unknown
- 2017-12-01 BR BR112019011334A patent/BR112019011334A2/pt not_active Application Discontinuation
- 2017-12-01 MX MX2019006066A patent/MX379710B/es unknown
- 2017-12-01 PL PL17817175T patent/PL3548026T3/pl unknown
- 2017-12-01 SI SI201730714T patent/SI3548026T1/sl unknown
- 2017-12-01 PT PT178171757T patent/PT3548026T/pt unknown
- 2017-12-01 CA CA3044364A patent/CA3044364A1/en active Pending
-
2021
- 2021-04-16 CY CY20211100335T patent/CY1124116T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019006066A (es) | 2019-09-10 |
| CY1124116T1 (el) | 2022-05-27 |
| MX379710B (es) | 2025-03-11 |
| BR112019011334A2 (pt) | 2019-10-15 |
| EA201991304A1 (ru) | 2019-12-30 |
| DK3548026T3 (da) | 2021-04-19 |
| US20200093812A1 (en) | 2020-03-26 |
| WO2018100557A1 (en) | 2018-06-07 |
| CN110022877B (zh) | 2023-06-23 |
| EP3548026A1 (en) | 2019-10-09 |
| SI3548026T1 (sl) | 2021-07-30 |
| US11938122B2 (en) | 2024-03-26 |
| JP2020500868A (ja) | 2020-01-16 |
| LT3548026T (lt) | 2021-05-25 |
| KR20190086766A (ko) | 2019-07-23 |
| CN110022877A (zh) | 2019-07-16 |
| JP7040798B2 (ja) | 2022-03-23 |
| HUE054346T2 (hu) | 2021-08-30 |
| AU2017370003A1 (en) | 2019-06-06 |
| AU2017370003B2 (en) | 2023-04-13 |
| PT3548026T (pt) | 2021-04-22 |
| ES2867300T3 (es) | 2021-10-20 |
| HRP20210576T1 (hr) | 2021-05-28 |
| PL3548026T3 (pl) | 2021-08-23 |
| KR102595034B1 (ko) | 2023-10-26 |
| EP3548026B1 (en) | 2021-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017370003B2 (en) | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease | |
| JP5249388B2 (ja) | 糖尿病の治療及び予防のためのフタリド誘導体の使用 | |
| US20130158077A1 (en) | Pharmaceutical compositions | |
| US20220409598A1 (en) | Method of controlling blood sugar level and treatment of diabetes and related conditions | |
| JP7549344B2 (ja) | 治療有効量の５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンを投与する方法 | |
| JP5679458B2 (ja) | 内臓脂肪重量の低下剤 | |
| WO2018131626A1 (ja) | 非アルコール性脂肪性肝疾患の予防及び治療薬 | |
| CA3102584A1 (en) | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts | |
| KR102200664B1 (ko) | 고혈당증의 치료 방법 | |
| EP3801515B1 (en) | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases | |
| KR102896709B1 (ko) | 신경 변성 질환의 예방 또는 치료약 | |
| CN1162152C (zh) | 糖尿病治疗剂 | |
| KR102784482B1 (ko) | 신경퇴행성 질환 및/또는 그것의 임상적 상태를 억제 및/또는 치료하기 위한 조성물 및 방법 | |
| HK40014768A (en) | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]ph-enyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease | |
| HK40014768B (en) | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]ph-enyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease | |
| HK40012325A (en) | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease | |
| EA040395B1 (ru) | Применение 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-диона или его фармацевтически приемлемой соли для лечения неалкогольной жировой болезни печени и способ лечения или предупреждения неалкогольной жировой болезни печени | |
| CN1703245A (zh) | 用于治疗肥胖的促进脂质和碳水化合物代谢的杂环化合物和抗氧剂的联合 | |
| JP2011001296A (ja) | インスリン分泌促進剤 | |
| HK1254471B (zh) | (r)-(+)-维拉帕米用於治疗高血糖的用途及其药学组合物 | |
| HK1126125A (en) | Remedy for diabetic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220920 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251111 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260106 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260112 |